ConductScience.org, home

Paper35836769

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.

Zhao X and 11 others. J Clin Transl Hepatol, 2022. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. Papers, record 35836769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35836769

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.
PubMed
Journal
J Clin Transl Hepatol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
1.38
iCite
Revised in PubMed
2022-07-16
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhao XXinyu
2Li MMin
3Wang HHao
4Xu XXiaoqian
5Wu XXiaoning
6Sun YYameng
7Ning CCanjian
8Wang BBingqiong
9Chen SShuyan
10You HHong
11Jia JJidonghttps://orcid.org/0000-0002-4673-8890
12Kong YYuanyuanhttps://orcid.org/0000-0002-2586-1443

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128418296Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China.Emerg Infect Dis2017https://conductscience.org/library/papers/28418296PubMed
225164003The global burden of liver disease: the major impact of China.Hepatology2014https://conductscience.org/library/papers/25164003PubMed
334590058Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.Lancet Reg Health West Pac2021https://conductscience.org/library/papers/34590058PubMed
435300634Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.BMC Cancer2022https://conductscience.org/library/papers/35300634PubMed
529599078Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.Lancet Gastroenterol Hepatol2018https://conductscience.org/library/papers/29599078PubMed
632077604Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.Liver Int2020https://conductscience.org/library/papers/32077604PubMed
731915601Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B.J Clin Transl Hepatol2019https://conductscience.org/library/papers/31915601PubMed
831941257[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].Zhonghua Gan Zang Bing Za Zhi2019https://conductscience.org/library/papers/31941257PubMed
933197397Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021https://conductscience.org/library/papers/33197397PubMed
1026268687Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study.Lancet Infect Dis2016https://conductscience.org/library/papers/26268687PubMed
1132255486Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.Clin Infect Dis2021https://conductscience.org/library/papers/32255486PubMed
1233414625Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs.Ann Gastroenterol2021https://conductscience.org/library/papers/33414625PubMed
1312512250New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers.Pharmacoepidemiol Drug Saf2002https://conductscience.org/library/papers/12512250PubMed
1435216027Current Trend in Antiviral Therapy for Chronic Hepatitis B.Viruses2022https://conductscience.org/library/papers/35216027PubMed
1528620797Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017https://conductscience.org/library/papers/28620797PubMed
1631956236"4+7" city drug volume-based purchasing and using pilot program in China and its impact.Drug Discov Ther2019https://conductscience.org/library/papers/31956236PubMed
1731231938Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.J Dig Dis2019https://conductscience.org/library/papers/31231938PubMed
1834760861The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.Front Public Health2021https://conductscience.org/library/papers/34760861PubMed
1930992636Countdown to 2030: eliminating hepatitis B disease, China.Bull World Health Organ2019https://conductscience.org/library/papers/30992636PubMed
2029405329Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.Hepatology2018https://conductscience.org/library/papers/29405329PubMed

See all 21 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42092899Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs.BMC Health Serv Res2026https://conductscience.org/library/papers/42092899PubMed
42050466Medication adherence and associated factors in patients with chronic hepatitis B in Zhejiang Province, Eastern China.BMC Public Health2026https://conductscience.org/library/papers/42050466PubMed
41787443Impact of a National Volume-Based Procurement Policy in China on purchase of nucleoside/nucleotide analog drugs for the treatment of chronic hepatitis B virus infection.BMC Public Health2026https://conductscience.org/library/papers/41787443PubMed
41306363Impact of Alanine Transaminase Thresholds on Treatment Eligibility of Patients with Chronic Hepatitis B: A Cross-sectional Study of the China Registry of Hepatitis B.J Clin Transl Hepatol2025https://conductscience.org/library/papers/41306363PubMed
41060358A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness.Curr Med Sci2025https://conductscience.org/library/papers/41060358PubMed
40595440Knowledge, attitudes, and practices of outpatients regarding National centralized drug procurement policy: a multicenter cross-sectional study in North China.Sci Rep2025https://conductscience.org/library/papers/40595440PubMed
38895618The impact of Chinese volume-based procurement on pharmaceutical market concentration.Front Pharmacol2024https://conductscience.org/library/papers/38895618PubMed
38176692Comprehensive approach to controlling chronic hepatitis B in China.Clin Mol Hepatol2024https://conductscience.org/library/papers/38176692PubMed
38042834The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.Trials2023https://conductscience.org/library/papers/38042834PubMed
37745061Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement.Front Pharmacol2023https://conductscience.org/library/papers/37745061PubMed
37731741A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China.Front Pharmacol2023https://conductscience.org/library/papers/37731741PubMed
37580251[Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study].Zhonghua Gan Zang Bing Za Zhi2023https://conductscience.org/library/papers/37580251PubMed
37243297The Impact of the Definitions of Clinical Phases on the Profiles of Grey-Zone Patients with Chronic Hepatitis B Virus Infection.Viruses2023https://conductscience.org/library/papers/37243297PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35836769

GET https://conductscience.org/api/papers/v1/35836769/references?page=2